President & CEO, John London, Nuvo Pharmaceuticals (NRI:TSX), explains how their company’s topical anti-inflammatory drugs are different from oral drugs.
I’m John London. I am the President and CEO of Nuvo Pharmaceuticals Inc. We’ve been successful in getting a number of products approved by the FDA that we’re selling and generating revenue. Our lead products are Pennsaid and Pennsaid 2% so both of those products are topical nsaids or non-steroidal anti-inflammatory drugs. The main problem that we are solving is the side effect issues of oral nsaids which are significant in the gastro-intestinal bleeding, the cardiovascular risk issues.
So the opportunity to have a topical that’s non systemic that really doesn’t get into the blood stream in any significant way but that works for arthritis, that’s a significant advancement. Original Pennsaid was approved several years ago and it’s sold in Canada, Europe, Greece, Italy the UK.
Pennsaid 2% which is the follow on product which is significantly improved in particular because it’s twice a day dosing as supposed to four times a day for original Pennsaid. It’s currently approved only in the United States, and our strategy is to roll that product out around the world throughout licensing transactions with partners that have a commercial presence in each of the geographic territories.
We have sales, we have profits and I think that as people see growing revenue and profitability that they will be fascinated by Nuvo Pharma as an investment.